Blue Earth reports Phase III data of imaging agent for prostate cancer treatment planning

Blue Earth Diagnostics Ltd. (London, U.K.) said that based on "successful results" of a pre-planned interim analysis, it halted enrollment in the Phase III Falcon trial of imaging agent Axumin [18F]-fluciclovine in patients with biochemical recurrence of prostate cancer being considered for curative intent salvage therapy. The interim data from 85 patients showed that 61% had their management plan changed after results of Axumin PET/CT imaging were added to the standard-of-care diagnostic work-up, the primary endpoint.

Secondary endpoints of the trial include response rate to radical salvage therapy, diagnostic performance and safety...